![Elena Ridloff](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Elena Ridloff
Finanzdirektor/CFO bei
SIONNA THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.05.2026
Profil
Ms. Elena H. Ridloff, CFA, ist ein unabhängiges Vorstandsmitglied bei Kymera Therapeutics, Inc. und ein unabhängiges Vorstandsmitglied bei Kronos Bio, Inc. sowie Chief Financial Officer & Executive Vice President bei ACADIA Pharmaceuticals, Inc. Sie ist Mitglied des Board of Directors bei Kymera Therapeutics, Inc. und Kronos Bio, Inc. Frau Ridloff war zuvor als Vice President-Investor Relations bei Alexion Pharmaceuticals, Inc. beschäftigt, als Chief Executive Officer & Managing Member bei BioVision, Inc. sowie als Senior Analyst bei Maverick Capital Ltd. und als Senior Analyst bei Paramount BioCapital Asset Management, Inc. Sie erwarb ihren Bachelor-Abschluss an der University of Pennsylvania.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.04.2026 | 38.532 ( 0,09 % ) | 2 Mio $ | 31.05.2026 |
Aktive Positionen von Elena Ridloff
| Unternehmen | Position | Beginn |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 12.03.2021 |
| SIONNA THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.01.2021 |
Ehemalige bekannte Positionen von Elena Ridloff
| Unternehmen | Position | Ende |
|---|---|---|
| KRONOS BIO, INC. | Direktor/Vorstandsmitglied | 20.06.2025 |
| ACADIA PHARMACEUTICALS INC. | Finanzdirektor/CFO | 10.09.2021 |
| ALEXION PHARMACEUTICALS, INC. | Investor Relations Kontakt | 01.03.2018 |
BioVision, Inc.
 BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Vorstandsvorsitzender | 01.04.2014 |
Maverick Capital Ltd.
 Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Analyst-Equity | 01.01.2012 |
Ausbildung von Elena Ridloff
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
95
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Paramount BioCapital Asset Management, Inc.
 Paramount BioCapital Asset Management, Inc. Investment ManagersFinance Paramount BioCapital Asset Management manages hedge funds and private equity funds that focus on investments in healthcare and life sciences companies. The firm invests globally, with emphasis on the stocks of small-cap healthcare technology companies. | Finance |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Finance |
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
BioVision, Inc.
BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kymera Therapeutics, Inc.
 Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Kronos Bio, Inc.
 Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
Stealth BioTherapeutics, Inc.
 Stealth BioTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat the mitochondrial dysfunctions and age-related diseases | Health Technology |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
